×
About 2,553 results

ALLMedicine™ Peritoneal Cancer Center

Research & Reviews  669 results

An Interventional Study of Avastin (Bevacizumab) in Patients With Advanced/Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer
https://clinicaltrials.gov/ct2/show/NCT01932125

Dec 2nd, 2021 - This multicenter prospective study will evaluate the safety and efficacy of Avastin (bevacizumab) in routine clinical practice in patients with advanced/metastatic epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer. Data...

A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib
https://clinicaltrials.gov/ct2/show/NCT02873962

Nov 29th, 2021 - This research study is a Phase II clinical trial. Cancers are recognized by the immune system, and under some circumstances,the immune system may control or even eliminate tumors. An antibody is a natural protein made by our immune system that bin...

A Study of RC48-ADC for the Treatment of HER2-expressing Gynecological Malignancies
https://clinicaltrials.gov/ct2/show/NCT04965519

Nov 25th, 2021 - This study is an open, multi-cohort, multi-center Phase II basket clinical study that included HER2 expression (HER2 positive and HER2 low expression) gynecological malignant tumor subjects. The four cohorts include cervical cancer, ovarian epithe...

Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
https://clinicaltrials.gov/ct2/show/NCT04095364

Nov 24th, 2021 - PRIMARY OBJECTIVE: I. To examine if letrozole monotherapy/maintenance (L/L) is non-inferior to intravenous (IV) paclitaxel/carboplatin and maintenance letrozole (CT/L) with respect to progression-free survival (PFS) in women with stage II-IV prima...

Study to Assess Safety and Efficacy of the Second Mitochondrial-derived Activator of Caspases (SMAC) Mimetic Debio 1143
https://clinicaltrials.gov/ct2/show/NCT04122625

Nov 23rd, 2021 - Part A (dose-optimization)- to determine the recommended phase 2 dose (RP2D) taking into account dose-limiting toxicity (DLT/s) in Cycle 1, overall safety/tolerability and pharmacokinetic (PK), by optimizing doses of Debio 1143 when combined with ...

see more →

Guidelines  5 results

PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline.
https://doi.org/10.1200/JCO.20.01924
Journal of Clinical Oncology : Official Journal of the Am... Tew WP, Lacchetti C et. al.

Aug 14th, 2020 - To provide recommendations on the use of poly(ADP-ribose) polymerase inhibitors (PARPis) for management of epithelial ovarian, tubal, or primary peritoneal cancer (EOC). Randomized, controlled, and open-labeled trials published from 2011 through 2...

Management of epithelial cancer of the ovary, fallopian tube, and primary peritoneum. L...
https://doi.org/10.1016/j.jogoh.2019.03.017
Journal of Gynecology Obstetrics and Human Reproduction; Lavoue V, Huchon C et. al.

Apr 3rd, 2019 - An MRI is recommended for an ovarian mass that is indeterminate on ultrasound. The ROMA score (combining CA125 and HE4) can also be calculated (grade A). In presumed early-stage ovarian or tubal cancers, the following procedures should be performe...

Practice Bulletin No. 182 Summary: Hereditary Breast and Ovarian Cancer Syndrome.
https://doi.org/10.1097/AOG.0000000000002285
Obstetrics and Gynecology Reference;

Aug 24th, 2017 - Hereditary breast and ovarian cancer syndrome is an inherited cancer-susceptibility syndrome characterized by multiple family members with breast cancer, ovarian cancer, or both. Based on the contemporary understanding of the origins and managemen...

Practice Bulletin No 182: Hereditary Breast and Ovarian Cancer Syndrome.
https://doi.org/10.1097/AOG.0000000000002296
Obstetrics and Gynecology;

Aug 24th, 2017 - Hereditary breast and ovarian cancer syndrome is an inherited cancer-susceptibility syndrome characterized by multiple family members with breast cancer, ovarian cancer, or both. Based on the contemporary understanding of the origins and managemen...

No. 344-Opportunistic Salpingectomy and Other Methods of Risk Reduction for Ovarian/Fal...
https://doi.org/10.1016/j.jogc.2016.12.005
Journal of Obstetrics and Gynaecology Canada : JOGC = Jou... Salvador S, Scott S et. al.

May 22nd, 2017 - This guideline reviews the potential benefits of opportunistic salpingectomy to prevent the development of high grade serous cancers (HGSC) of the ovary/fallopian tube/peritoneum based on current evidence supporting the fallopian tube origin of di...

see more →

Drugs  7 results see all →

Clinicaltrials.gov  145 results

An Interventional Study of Avastin (Bevacizumab) in Patients With Advanced/Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer
https://clinicaltrials.gov/ct2/show/NCT01932125

Dec 2nd, 2021 - This multicenter prospective study will evaluate the safety and efficacy of Avastin (bevacizumab) in routine clinical practice in patients with advanced/metastatic epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer. Data...

A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib
https://clinicaltrials.gov/ct2/show/NCT02873962

Nov 29th, 2021 - This research study is a Phase II clinical trial. Cancers are recognized by the immune system, and under some circumstances,the immune system may control or even eliminate tumors. An antibody is a natural protein made by our immune system that bin...

A Study of RC48-ADC for the Treatment of HER2-expressing Gynecological Malignancies
https://clinicaltrials.gov/ct2/show/NCT04965519

Nov 25th, 2021 - This study is an open, multi-cohort, multi-center Phase II basket clinical study that included HER2 expression (HER2 positive and HER2 low expression) gynecological malignant tumor subjects. The four cohorts include cervical cancer, ovarian epithe...

Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
https://clinicaltrials.gov/ct2/show/NCT04095364

Nov 24th, 2021 - PRIMARY OBJECTIVE: I. To examine if letrozole monotherapy/maintenance (L/L) is non-inferior to intravenous (IV) paclitaxel/carboplatin and maintenance letrozole (CT/L) with respect to progression-free survival (PFS) in women with stage II-IV prima...

Study to Assess Safety and Efficacy of the Second Mitochondrial-derived Activator of Caspases (SMAC) Mimetic Debio 1143
https://clinicaltrials.gov/ct2/show/NCT04122625

Nov 23rd, 2021 - Part A (dose-optimization)- to determine the recommended phase 2 dose (RP2D) taking into account dose-limiting toxicity (DLT/s) in Cycle 1, overall safety/tolerability and pharmacokinetic (PK), by optimizing doses of Debio 1143 when combined with ...

see more →

News  195 results

SL-172154 Shows Favorable Tolerability in Platinum-Resistant Ovarian Cancer
https://www.onclive.com/view/sl-172154-shows-favorable-tolerability-in-platinum-resistant-ovarian-cancer

Nov 17th, 2021 - The investigative agent SL-172154 (SIRPα-Fc-CD40L) was found to be well tolerated, with no dose-limiting toxicities (DLTs) observed, in patients with platinum-resistant ovarian cancer, according to findings from a phase 1 dose-escalation trial pre...

Nemvaleukin Alfa Plus Pembrolizumab Gets Fast Track Status for Platinum-Resistant Ovarian Cancer
https://www.onclive.com/view/nemvaleukin-alfa-plus-pembrolizumab-gets-fast-track-status-for-platinum-resistant-ovarian-cancer

Oct 26th, 2021 - The FDA has granted a fast track designation to the interleukin-2 (IL-2) variant immunotherapy nemvaleukin alfa (nemvaleukin) in combination with pembrolizumab (Keytruda) for the treatment of patients with platinum-resistant ovarian cancer.1 The ...

Studies Demonstrate Potential of Immunomodulation as Therapeutic Target in Gynecologic Cancers
https://www.onclive.com/view/studies-demonstrate-potential-of-immunomodulation-as-therapeutic-target-in-gynecologic-cancers

Oct 6th, 2021 - Russell Schilder, MD The renaissance in immunology is already affecting treatment paradigms for a variety of gynecologic cancers, and the impact is only likely to expand, Russell Schilder, MD, said during a recent presentation at the 9th Annual I...

Angiogenesis-Targeting Agents Poised to Become a Mainstay of Gynecologic Cancer Treatment
https://www.onclive.com/view/angiogenesis-targeting-agents-poised-to-become-a-mainstay-of-gynecologic-cancer-treatment

Oct 6th, 2021 - Robert A. Burger, MD Antiangiogenic agents hold promise in gynecologic cancers, as evidenced by their single-agent activity in malignancies including ovarian cancer, recurrent endometrial cancer, and cervical cancer. While the compounds are stil...

Harnessing Immune Response in Advanced Ovarian Cancer
https://www.onclive.com/view/harnessing-immune-response-in-advanced-ovarian-cancer

Oct 6th, 2021 - Mian M. Shahzad, MD, PhD Preliminary research has shown that harnessing the immune system can lead to potentially viable and efficacious therapies for patients with advanced ovarian cancer; therefore, combination approaches with checkpoint inhibi...

see more →